#NURIX

[bmv1]

Myntra co-founder Mukesh Bansal gets VC funding for new startup Nurix AI

Mukesh Bansal, the co-founder of online fashion major Myntra and Cult.fit, has secured $27.5 million in his new fundraising for artificial intelligence firm Nurix AI. This funding round combines seed investment and series A funding and was supported by Accel and General Catalyst.

Vision and Strategic Partnerships of Nurix AI

Nurix AI is primarily interested in offering AI-based customer communication tools. The kind of AI it seeks to incorporate into companies and organizations is to become functional agents within enterprises, boosting the effectiveness of their communication with an enterprise’s customers. Bansal believes that in the not-too-distant future, advanced intelligent agents supported by the human knowledge base will perform a great portion of work, generating unheard-of levels of efficiency and an increase in product quality.

Nurix AI intends to forge strategic collaborations with AI hardware and product makers. These partnerships help the company aim at the implementation of state-of-the-art AI technologies into the solutions, offering a competitive advantage in the market. Moreover, for Nurix AI, the improvement of the firm’s research & development functions will be vital so that its solutions remain cutting-edge in the field of AI. 

Funding Details

The $27.5 million raised shall play a critical role in accelerating the operations of Nurix AI. The collected funds will be utilized for the company’s improvement of its technological portfolio, strengthening research and development, and for the development of strategic collaborations with AI hardware and product providers. The strategic investment has been informed by the growing demand for artificial intelligence solutions across Asia & North America markets and its ability to address this space squarely will be strategic for Nurix AI.

Mukesh Bansal said, “At Nurix, we envision a future where AI agents, guided by human expertise, handle a significant portion of tasks, driving unprecedented gains in productivity and quality.” 

Entrepreneurial Journey of Mukesh Bansal

Mukesh Bansal co-founded Myntra in the same year and will be one of India’s most popular fashion e-tailers. Mukesh Bansal in 2014 managed to sell Myntra to his biggest rival Flipkart. Later, he started Curefit, a fitness services firm in 2021. It was renamed Cult.fit after receiving funding from Tata Digital. Mukesh Bansal was also the President of Tata Digital before he started his two-year sabbatical from the company in 2023.

Market Potential and Unique Approach

The overall AI market is rapidly growing and enterprises are choosing AI solutions more frequently to improve customer productivity and interaction. The market research shows that the AI market is projected to grow at a CAGR of 42.2% within the years 2020 to 2027. This growth of improvements in AI technology, growing investment, and the ever-growing need for AI solutions in various organizations.

Nurix AI has the opportunity to stand out as the company offering customer experience services enhanced by artificial intelligence, yet implemented jointly with human contributors. The first service offering is in the BPO sector and the company aims at helping enterprises have highly involved and productive conversations with their customers. With AI integration Nurix AI hopes to minimize the time and energy that customers have to spend interacting with the AI itself. 

Conclusion

The new startup founded by Mukesh Bansal, Nurix AI, will be the next major player in AI and customer engagement. After receiving $27.5 million in funding from Accel and General Catalyst, the firm is prepared for increased expansion of operations to meet demand. With the growth and development of Nurix AI, the field of customer interaction with companies through artificial intelligence will be influenced.

[nurixai]

Nurix AI

Product Name: GenAssist

Proof of Concept: GenAssist is a customized virtual assistant product based on Gen AI technology, designed to provide intelligent customer service and support for enterprises. With GenAssist, customers can get real-time and personalized help to meet their needs and solve problems, improve customer satisfaction and improve enterprise efficiency.

Product Features:

Real-time intelligent answers: GenAssist can use Gen AI technology to generate real-time, accurate answers and solutions based on the questions and needs provided by customers. Customers can get help without waiting for manual responses.

Personalized service: GenAssist can generate personalized suggestions and recommendations based on customers' historical data and personal preferences. By analyzing customers' preferences and behavior patterns, GenAssist can provide more accurate services.

Multi-channel support: GenAssist can flexibly integrate with multiple communication channels of enterprises, including website chat windows, in-app chat functions, and social media private messages, etc., to meet customer needs on different platforms.

Intelligent learning ability: GenAssist can continuously learn and optimize its answers and solutions, improve its intelligence level in continuous interaction, and better understand and meet customer needs.

Proof of concept method:

Build the GenAssist model: Based on the specific business needs of the enterprise, collect and prepare relevant data sets, and use OpenAI's technology platform to train the Gen AI model to generate intelligent customer answers and solutions.

Simulate customer scenario testing: Integrate GenAssist into the enterprise's customer service platform and simulate customer scenarios for testing. By interacting with simulated customers, verify whether GenAssist can accurately understand customer problems and provide real-time and personalized solutions.

User feedback and iteration: Collect user feedback and suggestions from simulated customer scenario testing, and continuously optimize GenAssist's performance and user experience. Through continuous iteration, ensure that GenAssist can meet customer needs and achieve the expected business results.

Through the above proof of concept process, enterprises can evaluate the feasibility and effectiveness of GenAssist and provide a basis for the development and launch of the final product.

[kkumarsblog]

Molecular Glue Market: Transforming the Landscape of Targeted Therapies

The molecular glue market is revolutionizing drug discovery by enabling the precise targeting of previously inaccessible proteins. These innovative molecules work by promoting selective protein degradation, offering a novel method for combating diseases such as cancer, neurodegenerative disorders, and autoimmune conditions.

With increasing scientific breakthroughs, the industry is on the verge of exponential growth, creating both challenges and opportunities for investors and pharmaceutical developers.

What is Molecular Glues?

Molecular glues are small molecules that promote proximity between two target proteins, typically facilitating interactions between a protein of interest and an E3 ligase, a key component of the ubiquitin-proteasome system. This system regulates protein turnover by tagging damaged or unwanted proteins for degradation. By leveraging this mechanism, molecular glues can selectively degrade disease-related proteins, such as oncogenic proteins in cancer.

Unlike conventional small-molecule inhibitors that block protein function, molecular glues enable direct protein degradation, offering a more dynamic and potent therapeutic strategy. This distinct mechanism provides new opportunities to address diseases that have been challenging to treat with traditional therapies.

The Role of Molecular Glues Market in Drug Discovery

Molecular glues have garnered significant interest due to their ability to target proteins that were previously considered undruggable. These proteins, often implicated in cancer, neurodegenerative diseases, and viral infections, pose structural challenges or lack well-defined binding sites, making them difficult to modulate with traditional drugs.

By utilizing the ubiquitin-proteasome system, molecular glues offer a novel approach to regulating these proteins. For instance:

Cancer: Molecular glues can induce the degradation of oncogenic proteins that drive tumor progression.

Neurodegenerative Diseases: They may help remove misfolded proteins that contribute to conditions such as Alzheimer's and Parkinson’s.

Autoimmune Diseases: By degrading overactive immune signaling proteins, molecular glues could provide new treatment options for conditions like rheumatoid arthritis and lupus.

Infectious Diseases: These compounds may target critical viral proteins, offering a promising avenue for antiviral drug development.

Leading Innovations in the Molecular Glue Companies

Several pharmaceutical and biotechnology companies are at the forefront of molecular glue research and development:

Arvinas: A pioneer in the field, Arvinas has developed the PROTAC (Proteolysis Targeting Chimeras) platform, which includes molecular glues designed for targeted protein degradation in cancer and neurological disorders.

Kymera Therapeutics: Specializing in targeted protein degradation, Kymera is advancing molecular glues for autoimmune diseases, cancer, and viral infections.

C4 Therapeutics: Utilizing PROTAC technology, C4 Therapeutics is developing targeted degradation therapies for cancer, incorporating advanced drug delivery approaches.

Nurix Therapeutics: Focusing on E3 ligases, Nurix is innovating molecular glue-based therapies for cancer and other diseases.

Market Trends and Growth Drivers

The molecular glue therapeutics market is expected to grow rapidly, driven by several factors:

Increasing Investment in Protein Degradation Technologies: Companies like Arvinas and Kymera are making groundbreaking advancements, attracting substantial research funding and investment.

Expanding Drug Discovery Pipelines: Pharmaceutical firms are integrating molecular glue technology into their pipelines, broadening the scope of potential therapeutics for complex diseases.

Regulatory Support: Agencies such as the FDA and EMA are facilitating approval pathways for molecular glue-based therapeutics, including accelerated approvals and orphan drug designations.

Strategic Collaborations: Partnerships between major pharmaceutical companies and biotech firms are accelerating research, clinical trials, and regulatory approvals.

Challenges and Opportunities in the Molecular Glue Market

Despite its potential, the molecular glue market faces several hurdles:

Toxicity and Off-Target Effects: Since molecular glues induce protein degradation, ensuring target specificity and minimizing unintended effects is crucial.

Biomarker Development: Identifying biomarkers that predict patient responses is essential for optimizing treatment success.

Manufacturing and Scalability: The complex synthesis of molecular glues requires advancements in production techniques to meet market demand.

Nevertheless, the market offers significant opportunities, particularly in oncology, neurodegenerative diseases, and autoimmune disorders. As research progresses, the application of molecular glue therapeutics is expected to expand across multiple therapeutic areas.

Conclusion

The molecular glue market is revolutionizing drug discovery and therapeutic development. By enabling the degradation of previously undruggable proteins, molecular glues are reshaping treatment approaches for various diseases. With growing investments, strategic collaborations, and regulatory advancements, the market is poised for rapid expansion. While challenges remain, the potential benefits for patients and the pharmaceutical industry are substantial, positioning molecular glues as a cornerstone of future medical innovations.

Top-Selling Market Research Reports in 2025

Thyroid Cancer Market | Type 1 Diabetes Market | Urinary Catheters Market | Venous Ulcer Market | Atopic Dermatitis Market | Avascular Necrosis Market | Diabetic Nephropathy Market | Orthopedic Power Devices Market | Positive Airway Pressure Device Market | Sepsis Market | Spinal Trauma Devices Market | Surgical Energy Instruments Market | Thrombectomy Devices Market | Vital Sign Monitors Devices Market | CXCR Inhibitors Market

About DelveInsight

DelveInsight is a premier market research and consulting firm specializing in the life sciences and healthcare sectors. With a focus on delivering actionable insights, DelveInsight empowers pharmaceutical, biotech, and medical device companies to make informed decisions in dynamic and competitive markets.

Contact Information Kanishk

kkumar@delveinsight.com

[wakeming]

'Holiday Witch Business: A Black Cat's View'

I used to be a solo cat. Now I live with Fiona and Jenny. They call me Nurix.

We met at the edge of the woods during a beautiful autumn sunset. Everything glowed with warm orange: the sky, the leaves, the wind, even some abandoned iron.

'Do you want to live with us?' They petted me softly with their gentle hands.

'Come, come.' The invitation felt natural.

We've been together for 189 days. They give me really good snacks, but I'm still an independent cat.

I found out that they are witches, so I guess I'm now a witch's cat, but I don't do magic.

They perform magic a lot—with accessories, with machines, sometimes with spells—causing lights and sounds to come out of nowhere.

I'm involved in all their business.

'Where we goin' this time for the holiday?' Fiona asked, one day.

'What about the beach?' Jenny said, reading a book.

So we flew here.

Sunbeams, sea breeze, golden sands, and big trees growing tasty seaweeds.

They are doing their holiday witch business on the beach.

As usual, I like hanging on Jenny's fluffy head.

Being independent and being present, I'd choose to stick with them longer and longer, I guess.

[mirrorworldmagazine]

Mukesh Bansal’s Nurix AI Secures $27.5 Million in Funding from Leading Venture Firms – Accel, General Catalyst, and Meraki Labs

San Francisco, CA – Mukesh Bansal’s Nurix AI has raised $27.5 million in funding from General Catalyst and Accel, with Meraki Labs, in its most recent fundraising round, which is a major step forward for the nascent field of artificial intelligence and healthcare. The investment, led by major venture capital firms Accel and General Catalyst, with investments from Meraki Labs, demonstrates the growing interest in AI-powered solutions for drug development and personalized treatment.

Nurix AI, founded in 2021, intends to transform pharmaceutical development by using advanced machine learning algorithms to predict how tiny compounds will interact with proteins in the human body. The company’s novel approach aims to speed up the drug discovery process, which has typically taken years and requires significant financial commitment.

The funding is a combination of seed and series A rounds. The company raised $12.5 million in early capital, with the remainder coming from Series A.

The investment will be used to enhance Nurix’s technological base and scale its activities in Asia and Northern America, according to a news release. This involves expanding its R&D skills and forming long-term relationships with AI hardware and product companies.

Transforming Drug Discovery

Mukesh Bansal, who co-founded the well-known firm Myntra before delving into the area of AI and biotech, is optimistic about Nurix AI’s ability to transform the pharmaceutical landscape. “Traditional drug discovery strategies are time-consuming and uncertain. “Our technology enables researchers to make more informed decisions earlier in the process, ultimately saving time and resources,” he explained in a recent interview.

Nurix AI’s technology uses cutting-edge deep learning techniques to scan large datasets, identifying possible medication candidates more accurately than traditional methods. Nurix AI’s algorithms predict drug efficacy and safety by combining biological, chemical, and clinical data, considerably increasing the likelihood of favorable clinical trial outcomes.

Read More: https://mirrorworldmagazine.com/mukesh-bansals-nurix-ai-secures-27-5-million-in-funding-from-leading-venture-firms-accel-general-catalyst-and-meraki-labs/

[businessindustry]

Molecular Glues Market Application, Growth 2024-2032

The Reports and Insights, a leading market research company, has recently releases report titled “Molecular Glues Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Molecular Glues Market Size share, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Molecular Glues Market?

According to Reports and Insights analysis, the global molecular glues market is expected to register a revenue CAGR of 5.8% during the forecast period of 2024-2032.

What are Molecular Glues?

Molecular glues are small molecules capable of binding to two different proteins simultaneously, thereby effectively "gluing" them together. This characteristic enables them to modulate interactions between proteins, influencing various cellular functions. Molecular glues have garnered considerable interest in drug discovery and development because they can target protein complexes that are difficult to inhibit using conventional methods. They present a promising strategy for creating new treatments for diseases like cancer, neurodegenerative disorders, and viral infections, by selectively targeting specific protein interactions crucial for the advancement of these conditions.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/1609

What are the growth prospects and trends in the Molecular Glues industry?

The molecular glues market growth is driven by various factors. The molecular glues market is experiencing significant growth, primarily due to the increasing emphasis on drug discovery and development. Molecular glues are essential for modulating interactions between proteins, making them invaluable in addressing complex diseases. Factors such as the rising incidence of chronic diseases, growing demand for targeted therapies, and advancements in molecular biology are propelling market expansion. Moreover, the rising investment in research and development focused on molecular glues is expected to drive further market growth. Hence, all these factors contribute to molecular glues market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Product Type:

Proteolysis-Targeting Chimeras (PROTACs)

Specific and Nongeneric Protein Degraders

Other Molecular Glues

Application:

Oncology

Genetic Disorders

Neurological Disorders

Infectious Diseases

Other Therapeutic Areas

End-user:

Pharmaceuticals and Biotechnology Companies

Research Institutes and Academia

Contract Research Organizations (CROs)

Others

Research Focus:

Preclinical Studies

Clinical Trials

Post-market Surveillance

Segmentation By Region:

North America:

United States

Canada

Europe:

Germany

The U.K.

France

Spain

Italy

Russia

Poland

BENELUX

NORDIC

Rest of Europe

Asia Pacific:

China

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America:

Brazil

Mexico

Argentina

Middle East & Africa:

Saudi Arabia

South Africa

United Arab Emirates

Israel

Who are the key players operating in the industry?

The report covers the major market players including:

Arvinas Inc.

C4 Therapeutics

Kymera Therapeutics

Nurix Therapeutics

Bristol Myers Squibb

Boehringer Ingelheim

AstraZeneca

Genentech (a member of the Roche Group)

GlaxoSmithKline

Novartis

Pfizer Inc.

Takeda Pharmaceuticals

Merck & Co., Inc.

Amgen Inc.

Vertex Pharmaceuticals

View Full Report: https://www.reportsandinsights.com/report/Molecular Glues-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[fmarkets]

'''Urgent'Measures'Required'to'Reverse'the'Financial'Downturn'at'Nurix'Therapeutics'Inc $NRIX #Nasdaq

NRIX announced second quarter of 2024 operating shortfall of $-48.54 millionInterpreting the financial results of a major pharmaceutical preparations company can be both enlightening and concerning. In the case of Nurix Therapeutics Inc, the disclosed figures for the period of March to May 31, 2024, paint a rather disastrous picture. Revenue has experienced a significant decline of -60.582% to $12.09 million, while the net loss per share has widened to $-0.71. Comparing these results to the same financial reporting period a year ago, it

[hopetribune]

Chronic Lymphocytic Leukemia Market Is Projected to Grow at a Moderate Growth Rate During the Forecast Period | Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics

http://dlvr.it/T6WKyK

[conversationpoint]

Chronic Lymphocytic Leukemia Market Anticipated to Expand by 2032, as Projected by DelveInsight | Loxo Oncology, Oncternal Therapeutics, Novartis, AstraZeneca, Nurix Therapeutics, Merck

http://dlvr.it/T5ZRms

[thealphareporter]

CNS Lymphoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Kazia Therapeutics, Cellectar, Ono Pharma, Nurix Therapeutics

http://dlvr.it/SyZy8n

[biotech-news-feed]

The alliance, which aims to combine Seagen’s antibody expertise with Nurix’s targeted protein degradation research, comes as the larger biotech awaits its acquisition by Pfizer to close. #BioTech #science

[lindamacdonaldavanir]

Seagen partners with Nurix to create new kind of cancer drug

Seagen partners with Nurix to create new kind of cancer drug https://ift.tt/rZ3xDRJ The alliance, which aims to combine Seagen’s antibody expertise with Nurix’s targeted protein degradation research, comes as the larger biotech awaits its acquisition by Pfizer to close.  via BioPharma Dive - Latest News https://ift.tt/qcQsv09 September 07, 2023 at 12:20PM

[columbianewsupdates]

CNS Lymphoma Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),|Key Companies – Pentixa Pharmaceuticals, Ono Pharmaceuticals, Prelude Therapeutics, Nurix Ther

http://dlvr.it/SnkvMn

[craftgender]

ADnurix:

A gender that is caused by the Attention Deficit in ADHD.

This gender is basically “Executive Dysfunction: Gender Edition”. It’s somewhere in the brain fog. You just don’t know where it is just yet. The gender was just here a second ago, I’ll find it, I swear.

This term can only be used by people with ADHD

Coined By: @term-hoarder

[hikingofthenoldor]

In an attempt to keep my art and OC tags clutter free, here is my wacky little doodle of my OC Nurix again on its own - inspired by this post.